AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for ...

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

A review evaluated the distribution and predictive capabilities of three genomic assays for breast cancer across different ...

Apr. 2, 2025 — Scientists are working to create a new light-activated 'smart' bomb to treat aggressive breast cancer. The new light-sensitive chemicals called cyanine-carborane salts are used in ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

The five-year stage 3 breast cancer survival rate is 86.3%. This means roughly 86.3% of those with stage 3 breast cancer will still be alive five years after diagnosis. Cancer survival depends on many ...

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunothera ...